The global pet diagnostic reagents and equipment market is experiencing rapid expansion, fueled by rising pet ownership, increased healthcare spending on companion animals, and significant technological advancements.
I. Market Size and Growth Trajectory
1.1 Overall Market Size
The pet diagnostics market can be measured through several different scopes:
Market Scope | 2025 Size | 2026 Size | Forecast Size | CAGR |
Global Veterinary Diagnostics Market (reagents & equipment) | $8.78 billion | $9.72 billion | $21.59 billion (2034) | 10.50% |
Global Veterinary Rapid Test Kits Market | $604 million | — | $1.007 billion (2032) | 7.7% |
Global Veterinary Diagnostic Equipment Market | $3.94 billion | $4.29 billion | $7.34 billion (2032) | 9.28% |
U.S. Veterinary Diagnostics Market | — | $2.41 billion | $3.74 billion (2031) | 9.1% |
European Companion Animal Diagnostics Market | — | $460 million | $700 million (2031) | 8.6% |
On a broader scale, the global animal therapeutics and diagnostics market is estimated at $51.62 billion in 2025 and is projected to reach $54.9 billion in 2026, with a CAGR of 6.4%. The veterinary diagnostic services market alone stands at $14.22 billion in 2025, expected to hit $15.47 billion in 2026, growing at 8.8% annually.
1.2 Market Structure
By product type, reagents and consumables dominate the market and are expected to account for 76.69% of total revenue in 2026. This segment's growth is attributed to increasing veterinary testing frequency and rising expenditure worldwide.
By technology platform, immunodiagnostics leads the market (expected to capture 25.33% in 2026), driven by its expanding applications and proven utility as a practical tool for diagnosing animal diseases. Molecular diagnostics is also growing rapidly, particularly with the application of PCR and next-generation sequencing technologies.
By animal type, the companion animal (pet) segment holds a slightly larger market share, expected to reach 51.96% in 2026, primarily driven by increasing pet care expenditure.
By end user, the veterinary reference laboratory segment is projected to account for 47.41% of the market in 2026, as reference laboratories gain importance due to their high diagnostic practice standards and data reliability.
II. Key Market Drivers
Global pet ownership rates continue to climb, directly driving diagnostic demand:
l United States: 66% of households own pets (approximately 94 million homes), up significantly from 62% in 2022
l China: The urban pet (dog and cat) consumer market reached 312.6 billion yuan in 2025, representing 4.1% year-on-year growth; annual spending per dog reached 3,006 yuan and per cat reached 2,085 yuan — both record highs
Pets are increasingly regarded as "family members," prompting owners to invest more readily in healthcare services, including preventive treatments and advanced diagnostics.
The rising incidence of zoonotic and infectious diseases is driving diagnostic demand:
l U.S. CDC and other agencies have identified eight major zoonotic diseases of concern: West Nile virus, influenza, coronavirus, salmonellosis, plague, rabies, brucellosis, and Lyme disease
l Europe reported increased campylobacteriosis and salmonellosis cases in 2021 compared to 2020, with EIA or PCR as the common detection methods
As human-pet relationships deepen and pet lifespans extend, the market for specialty pharmaceuticals and precision diagnostics is particularly pronounced. Early disease detection and preventive animal healthcare measures are receiving increasing attention.
Government agencies are actively funding diagnostic infrastructure development:
l In November 2023, Michigan State University's Veterinary Diagnostic Laboratory received USDA funding to enhance early disease detection capabilities in the Midwest region
l Industry players worldwide are actively establishing new diagnostic laboratories
III. Technology Trends
AI is transforming veterinary diagnostic workflows:
Company/Product | AI Application | Key Features |
IDEXX Vetscan Imagyst | AI-assisted cytology, fecal, dermatology diagnostics | Real-time diagnostic results with AI-driven insights |
Zoetis VETSCAN Series | AI blood smear analysis, AI urine sediment analysis, AI mass analysis | VETSCAN OptiCell completes CBC in 5 minutes |
SK Telecom X Caliber | AI-driven X-ray imaging diagnostics | Analyzes canine/feline X-rays in 15 seconds, 86%-94% sensitivity |
SMARTSOUND | AI-powered pet stethoscope | Records 20-second heart sounds to identify cardiac murmurs, enables early home screening |
Point-of-care testing technology is improving diagnostic speed and accessibility:
l Randox Laboratories launched VeraSTAT-V and VeraSTAT for equine health POCT diagnostics in 2022
l POCT technology requires limited medical personnel, helping overcome cross-training and experience gaps
l In June 2024, SK Telecom deployed its X Caliber system in over 100 veterinary clinics across Australia, with plans for global expansion.
The 93rd China International Medical Equipment Fair (CMEF) showcased several innovative products:
Pet-Specific Multifunctional CT Scanner (Weitu Medical) :
l Integrates CT, DR, and DSA angiography functions
l Single-rotation scanning (human CTs require multiple rotations), priced at just one-third of human CT systems
l Occupies only 7 square meters; targets hundreds of unit sales in 2026
Veterinary Laser Therapy Device (Weimai Medical) :
l Supports both therapeutic treatment and tumor/polyp excision
l Offers preset protocols based on animal species (dog/cat/horse), disease type, and body weight
l Reduces long-term medication burden on pets' esophagi and kidneys
Pet-Adapted Nebulizer (Ruitai) :
l Designed for respiratory conditions including feline herpesvirus, kennel cough, and asthma
l Available in hood, mask, and chamber configurations to accommodate different pet anatomical structures
l Launched in 2025; home-use features facilitate at-home treatment
Cargill launched its Zoonivet digital pet care application in 2023, connecting pet owners with licensed veterinarians through video consultations, with plans to offer surgery, home diagnostics, and drug delivery services in India
IDEXX has strengthened its VetConnect PLUS cloud platform for real-time diagnostic results and analysis
The migration and adaptation of human medical innovations to pet applications is an emerging trend, with technological development focused on two directions: high-precision, portable devices to improve clinical efficiency, and localized supply chains to optimize cost structures while maintaining quality.
IV. Competitive Landscape
The top five companies in the U.S. veterinary diagnostics market are: IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Antech Diagnostics, and bioMérieux.
Company | Core Strengths | Key Products / Recent Developments |
IDEXX Laboratories | Market leader, focus on CAG segment | Catalyst One, ProCyte Dx, SNAP tests, VetConnect PLUS platform; CAG R&D investment increased to $236.2 million in 2022 |
Zoetis | Widest product portfolio | VETSCAN series (VS2, Imagyst, OptiCell); $614 million R&D investment in 2023; launched VETSCAN OptiCell (AI blood cell analyzer) in May 2024 |
Thermo Fisher Scientific | Molecular diagnostics strength | VetMAX PCR solutions, QuantStudio platforms; focuses on zoonotic disease surveillance and biosafety |
Mars, Incorporated | Expansion through acquisitions | Petcare division encompasses extensive veterinary services and diagnostics across 15 countries |
China Mindray Animal Medical | Emerging Asia-Pacific player | Entering European companion animal diagnostics market as a Chinese representative |
l High R&D investment growth: IDEXX's CAG R&D investment increased from $140.6 million in 2021 to $236.2 million in 2022 (67.2% growth)
l Portfolio expansion: IDEXX launched new tests including Fecal Dx, FGF-23, and PCR Direct in 2022
l AI and digitalization as strategic focus: Companies universally view AI, cloud platforms, and data analytics as key differentiators
l Mergers and acquisitions: Enhancing diagnostic capabilities and geographic coverage through strategic acquisitions
V. Regional Market Analysis
l Holds 47.82% global market share in 2025
l Driving factors: High pet ownership rate (66% of households), high pet care spending, favorable reimbursement plans, dense veterinary service network
l Tariff impact: 2025 U.S. tariff policies have increased import costs for diagnostic equipment, prompting accelerated supply chain localization
l Germany: Pet population reached 33.4 million in 2022, pet industry turnover nearly €6.5 billion
l United Kingdom: Veterinary service spending rose from £2.6 billion in 2015 to £4.0 billion in 2021 (54% growth over six years)
l Regulatory coordination and public surveillance programs driving advanced diagnostic demand
l China: Pet-owning households surpassed 100 million in 2023, pet market reached 129.6 billion yuan, pet pharmaceutical and healthcare accounting for 9%. Increasing awareness of zoonotic diseases and rising disposable income driving growth
l Japan: Key Asia-Pacific market with increasing awareness of zoonotic disease risks and animal health expenditure
l Characteristics: Rapid veterinary service expansion, significant investment in livestock disease surveillance, high adoption rates of automated analyzers and molecular platforms
l Significant infrastructure disparities; cost-effective reagents and multiplex testing prioritized in resource-constrained regions
l Growing mobile and field diagnostic services
VI. Challenges and Risks
According to Mars Veterinary Health research, the United States will need approximately 41,000 additional veterinarians by 2030 to meet pet care demand
Common diagnostic laboratory challenges include: insufficient equipment or reagents, high costs, and inadequate laboratory staffing or training
2025 U.S. tariff frameworks have increased costs for imported diagnostic equipment, rapid test kits, and imaging devices
Affects pricing and procurement cycles while simultaneously encouraging local manufacturing and innovation
Companies are adopting dual sourcing strategies, maintaining critical component inventory, and selective nearshoring to mitigate trade policy volatility
Significant regulatory requirement variations across regions require companies to navigate complex approval processes
Veterinary pharmaceuticals in China are gradually diversifying, with accompanying medical devices developing accordingly
VII. Summary and Outlook
The pet diagnostic reagents and equipment market is in a high-growth trajectory, with the global veterinary diagnostics market expected to maintain approximately 10.5% compound annual growth from 2026 to 2034. Core development trends can be summarized as:
u Technology integration: Deep integration of AI, molecular diagnostics, and point-of-care testing with pet-specific devices, improving diagnostic accuracy and accessibility
u Setting expansion: Diagnostics expanding from professional hospitals to home settings, with AI stethoscopes, home-use nebulizers, and similar products promoting home screening adoption
u Regional divergence: North America dominant but stabilizing growth, Asia-Pacific emerging as growth engine, Chinese companies beginning global competition
u Competition escalation: Shift from single-product competition to ecosystem competition encompassing "hardware + software + services," with AI and digitalization as strategic high ground
u Supply chain restructuring: Trade policy uncertainty driving regionalized production layouts, balancing cost optimization with supply chain resilience
Future market growth will continue to be driven by precision animal medicine demand, increased emphasis on early detection, expanded preventive animal healthcare measures, and growing adoption of in-practice diagnostics.
CN
